Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BMY
Bristol-Myers Squibb, Cerner, General Motors, Monsanto: Fast Money Picks For November 25
Can Trump Make Your Portfolio Great Again?
Heat Biologics' lead product candidate flunks mid-stage bladder cancer study; shares plummet 56% (Seeking Alpha)
Related GNRC
The Hurricane Matthew Disaster Play Selloff
With Hurricane Matthew Picking Up Steam, Investors Are Piling Into This Generator Stock

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy
Oct 2016Credit SuisseMaintainsNeutral
Sep 2016CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

View Comments and Join the Discussion!